On March 11, 2025 Cue Biopharma reported the Ninth Amendment to the Collaboration, License and Option Agreement (the "Ninth Amendment") is entered into as of the last signature set forth below (the "Ninth Amendment Effective Date"), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 40 Guest Street, Boston, MA 02135 ("Cue"), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea ("LGC"). Cue and LGC may be referred to herein individually as a "Party" or collectively as the "Parties".
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Whereas, the Parties entered into a Collaboration, License and Option Agreement as of November 6, 2018 (the "Original Agreement") that was subsequently amended on March 15, 2019, August 5, 2019, October 29, 2019, December 18, 2019, January 10, 2020, February 14, 2020, May 14, 2020 and December 7, 2020 (the "First Amendment", "Second Amendment", "Third Amendment", "Fourth Amendment", "Fifth Amendment", "Sixth Amendment", "Seventh Amendment" and "Eighth Amendment", respectively, and collectively with the Original Agreement, the "Agreement");
Whereas, under the Agreement, Cue granted to LGC, inter alia, certain licenses, sublicenses and other rights relating to the CUE-101 Program, including the right to use, Research, Develop, Manufacture, Commercialize and otherwise exploit CUE-101 Compounds, and Collaboration Products that consist of or contain a CUE-101 Compound in any dosage form or formulation or mode of administration alone or in combination with one or more other therapeutically active ingredients (such products hereinafter "CUE-101 Products") in the Field in the LGC Territory; and
Whereas, Cue desires to acquire all of LGC’s rights in the CUE-101 Program (the "LGC CUE-101 Program Rights"), and LGC desires to terminate all of its rights under the CUE-101 Program, including the CUE-101 Compounds and CUE-101 Products, pursuant to Section 13.2(a) of the Agreement in exchange for the consideration set forth herein, and the Parties are entering into this Ninth Amendment to set forth the consideration agreed to between the Parties pursuant to Section 13.3(c)(iii) of the Agreement and to clarify the terms pursuant to which all LGC CUE-101 Program Rights would revert back to Cue.
Now, Therefore, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Cue and LGC hereby agree as follows:
1.
All capitalized terms used (including in the recitals) but not separately defined in this Ninth Amendment shall have the meaning ascribed to them in the Agreement.
The Parties acknowledge and agree that the Agreement is hereby terminated by LGC for convenience under Section 13.2(a) of the Agreement as to the CUE-101 Program effective as of the Ninth Amendment Effective Date, and for purposes of the Agreement, notice of termination will be deemed to have occurred on the Ninth Amendment Effective Date notwithstanding any notice period requirement. From and after the Ninth Amendment Effective Date, the CUE-101 Compounds and CUE-101 Products will become Terminated Products. Without limiting the generality of the foregoing, it is understood and agreed that (i) HPV16 shall no longer be deemed a Collaboration Antigen, (ii) Collaboration Compounds shall no longer include CUE-101 Compounds, and (iii) Collaboration Products shall no longer include CUE-101 Products; in each case, except that, for purposes of licenses to Cue under Sections 2.4(a), 2.4(b) and 2.4(c) of the Agreement that survive termination pursuant to Section 13.3(c) of the Agreement, the references to Collaboration Compounds and Collaboration Products in such sections will be deemed to include the Terminated Products that were formerly the CUE-101 Compounds and CUE-101 Products. Cue acknowledges and agrees that, as of the Effective Date, LGC has fully complied with all of LGC’s obligations under the Agreement to pay any payment or reimburse any amount to Cue related to the CUE-101 Program prior to the Ninth Amendment Effective Date, and no such obligation remains outstanding as of the Ninth Amendment Effective Date.
2.
For purposes of termination of the CUE-101 Program only, the Parties agree that Section 13.6 of the Agreement is hereby deleted in its entirety and replaced with the following:
"Except as set forth in the Ninth Amendment, neither Party will have any rights or obligations under the Agreement with respect to the CUE-101 Program after the Ninth Amendment Effective Date except:
(a) termination of this Agreement with respect to the CUE-101 Program shall not relieve the Parties of any obligation or right accrued under the CUE-101 Program prior to the Ninth Amendment Effective Date; and
(b) the obligations and rights of the Parties under the following provisions of this Agreement to the extent applicable to the CUE-101 Program shall survive termination of this Agreement with respect to the CUE-101 Program: Article VII (solely to the extent obligations accrued prior to the date of termination), Article VIII, Article XI (excluding Section 11.4), Article XII, Article XIV, and Article XV (except that Section 15.6(a) will not be deemed to prohibit transfer of Cue’s rights under the licenses with respect to the Terminated Products under Section 13.3(c)(iii)), the last sentence of Section 4.15, and Sections 9.1(a)-(b) and (d), 9.3(i), 9.10(a)- (d), 10.1, 13.3, 13.5, 13.6, 13.7, 13.8 and 13.9. "
3.
Pursuant to Section 13.3(c)(iii) of the Agreement and in consideration for the reversion of all LGC CUE-101 Program Rights back to Cue pursuant to this Ninth Amendment, the Parties have agreed that Cue will make payments to LGC according to one or more of the following scenarios, if and when applicable.
(i) Royalties on Net Sales of CUE-101 Products in the LGC Territory
Cue will make Calendar Quarterly the following non-refundable royalty payments to LGC according to the royalty rates set forth below based on Net Sales in the LGC Territory for the Royalty Term, with the royalties calculated according to (i) the Net Sales definition in Section 1.245 of the Agreement (with CUE-101 Product substituted for Collaboration Products and "Sublicensees" defined as any Third Party to which Cue has granted a license of its rights with respect to the CUE-101 Product (including a sublicense of its rights under Section 13.3(c)(iii) of the Agreement), and otherwise mutatis mutandis), and (ii) the provisions for Royalty Term, Royalty Step Down, Royalty Offsets and Royalty Floor as set forth in Sections 7.6(b)-(e) of the Agreement (with CUE-101 Products substituted for Collaboration Products).
(Filing, Cue Biopharma, MAR 11, 2025, View Source [SID1234663871])